Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

22.24
+0.56002.58%
Volume:197.76K
Turnover:4.33M
Market Cap:1.43B
PE:-6.41
High:22.30
Open:21.62
Low:21.16
Close:21.68
52wk High:22.54
52wk Low:5.68
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.46
T/O Rate:0.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:4.45
PE(LYR):-5.97

Loading ...

Why Cullinan Therapeutics (CGEM) Is Up 6.6% After Zipalertinib’s Positive Phase 3 Lung Cancer Data And What's Next

Simply Wall St.
·
Aug 22

Cullinan, Taiho say results of Phase 3 trial selected for presentation

TIPRANKS
·
Aug 20

Cullinan Says Rezilient3 Interim Data for Zipalertinib Plus Chemotherapy in EGFR Exon 20 NSCLC Lands IASLC WCLC 2026 Presidential Symposium Slot

Reuters
·
Aug 20

UBS Adjusts Cullinan Therapeutics Price Target to $27 From $24, Maintains Buy Rating

MT Newswires Live
·
Aug 17

Morgan Stanley Keeps Their Buy Rating on Cullinan Management (CGEM)

TIPRANKS
·
Aug 17

Cullinan Therapeutics Price Target Maintained with a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 17

Cullinan Therapeutics price target raised to $47 from $46 at Clear Street

TIPRANKS
·
Aug 17

Cullinan Therapeutics CSO Jennifer Michaelson Disposes of 30,000 Common Shares Worth $607,800

Reuters
·
Aug 15

U.S. Stocks on the MOVE-EnerSys, Netflix, Salesforce

Reuters
·
Aug 14

Cullinan Management (CGEM) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Aug 13

Cullinan Therapeutics Shares Reverse Premarket Course; Last Down 4.2%

THOMSON REUTERS
·
Aug 13

Sector Update: Healthcare Stocks Advance Pre-Bell Thursday

MT Newswires Live
·
Aug 13

Cullinan Therapeutics Price Target Raised to $42.00/Share from $39.00 by Wedbush

Dow Jones
·
Aug 13

Wedbush Adjusts PT on Cullinan Therapeutics to $42 From $39, Maintains Outperform Rating

MT Newswires Live
·
Aug 13

Cullinan Therapeutics Shares Rise 12.3% Premarket After Lung Cancer Drug Meets Late-Stage Trial Goal

THOMSON REUTERS
·
Aug 13

Cullinan Therapeutics, - Zipalertinib Arm Shows Significant Improvement in Progression-Free Survival with Manageable Safety

THOMSON REUTERS
·
Aug 13

Cullinan Therapeutics, - Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 Rezilient3 Trial

THOMSON REUTERS
·
Aug 13

Cullinan Therapeutics, - Taiho Oncology, Taiho Pharmaceutical, Cullinan Therapeutics to Pursue U.S. Regulatory Approval for Zipalertinib Combination

THOMSON REUTERS
·
Aug 13

Cullinan Climbs as Lung Cancer Drug Meets Late-Stage Trial Goal

Reuters
·
Aug 13

Otsuka Holdings Co., Ltd. - Zipalertinib Plus Chemotherapy Meets Primary Pfs Endpoint in Planned Interim Analysis of Phase 3 Rezilient3 Trial

Reuters
·
Aug 13